These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 15788205)

  • 1. Treatment with inhibitors of angiogenesis in advanced hepatocellular carcinoma: a new tool in our hands or simply a hope?
    Cipriani G; Mazzanti R
    Dig Liver Dis; 2005 Apr; 37(4):230-1. PubMed ID: 15788205
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of the combined treatment with thalidomide, megestrol and interleukine-2 in cirrhotic patients with advanced hepatocellular carcinoma. A pilot study.
    Cappa FM; Cantarini MC; Magini G; Zambruni A; Bendini C; Santi V; Bernardi M; Trevisani F
    Dig Liver Dis; 2005 Apr; 37(4):254-9. PubMed ID: 15788209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis blockade as therapy for hepatocellular carcinoma: progress and challenges.
    Hao CY
    J Gastroenterol Hepatol; 2011 Jan; 26(1):4-6. PubMed ID: 21175786
    [No Abstract]   [Full Text] [Related]  

  • 4. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
    Pinter M; Wichlas M; Schmid K; Plank C; Müller C; Wrba F; Peck-Radosavljevic M
    Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1012-9. PubMed ID: 18787470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting vessels to treat hepatocellular carcinoma.
    Romanque P; Piguet AC; Dufour JF
    Clin Sci (Lond); 2008 Apr; 114(7):467-77. PubMed ID: 18302534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thalidomide for advanced hepatocellular carcinoma: is this a real alternative?
    Wadler S
    Cancer; 2005 Jan; 103(1):1-4. PubMed ID: 15565637
    [No Abstract]   [Full Text] [Related]  

  • 7. Megestrol treatment in patients with hepatocellular carcinoma.
    Farinati F; Gianni S; De Giorgio M; Fiorentini S
    Br J Cancer; 2001 Nov; 85(10):1606-8. PubMed ID: 11720452
    [No Abstract]   [Full Text] [Related]  

  • 8. Antiangiogenic strategies in hepatocellular carcinoma: current status.
    Zacharoulis D; Hatzitheofilou C; Athanasiou E; Zacharoulis S
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):645-56. PubMed ID: 16111465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful targeted therapies for hepatocellular carcinoma: are we really getting there?
    Zhu AX
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):499-505. PubMed ID: 18402516
    [No Abstract]   [Full Text] [Related]  

  • 10. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma.
    Pang R; Poon RT
    Cancer Lett; 2006 Oct; 242(2):151-67. PubMed ID: 16564617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of thalidomide in hepatocellular carcinoma: assessment with power doppler US and analysis of circulating angiogenic factors.
    Hsu C; Chen CN; Chen LT; Wu CY; Hsieh FJ; Cheng AL
    Radiology; 2005 May; 235(2):509-16. PubMed ID: 15858091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Molecular structure and abnormal expression of angiopoietin-2 and antiangiogenic targeting therapy of hepatocelluar carcinoma].
    GU WJ; YAO DF
    Zhonghua Gan Zang Bing Za Zhi; 2009 May; 17(5):398-400. PubMed ID: 19497214
    [No Abstract]   [Full Text] [Related]  

  • 13. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors.
    Villa E; Ferretti I; Grottola A; Buttafoco P; Buono MG; Giannini F; Manno M; Bertani H; Dugani A; Manenti F
    Br J Cancer; 2001 Apr; 84(7):881-5. PubMed ID: 11286465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma.
    Chen LT; Liu TW; Chao Y; Shiah HS; Chang JY; Juang SH; Chen SC; Chuang TR; Chin YH; Whang-Peng J
    Aliment Pharmacol Ther; 2005 Aug; 22(3):217-26. PubMed ID: 16091059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
    Pang RW; Poon RT
    Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular changes in hepatocellular carcinoma.
    Yang ZF; Poon RT
    Anat Rec (Hoboken); 2008 Jun; 291(6):721-34. PubMed ID: 18484619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Inhibitory effect of thalidomide on growth of human hepatoma cell line SMMC-7721 cells].
    Sun P; Zhang LM; Sun DJ; Dong LL
    Zhonghua Zhong Liu Za Zhi; 2009 Aug; 31(8):582-6. PubMed ID: 20021944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature.
    Kaseb AO; Hanbali A; Cotant M; Hassan MM; Wollner I; Philip PA
    Cancer; 2009 Nov; 115(21):4895-906. PubMed ID: 19637355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Does anti-estrogen therapy after estrogen receptor analysis have value in palliative therapy of hepatocellular carcinoma?].
    Kreysel C; Porschen R
    Z Gastroenterol; 1998 Jul; 36(7):605-7. PubMed ID: 9738309
    [No Abstract]   [Full Text] [Related]  

  • 20. New strategy of antiangiogenic therapy for hepatocellular carcinoma.
    Wu XZ
    Neoplasma; 2008; 55(6):472-81. PubMed ID: 18999874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.